Evidence map›Paper›PMID 35482553›Full record

ArticleHematological oncology2022

Targeting MYC and BCL2 by a natural compound for "double-hit" lymphoma.

Xiaoqian Liu, Senlin Xu, Jiawei Zhang, Mingjie Fan, Jun Xie, Bingfeng Zhang, Hongzhi Li, Guohua Yu, Yinghui Liu, Yuanfeng Zhang and 5 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Hematological oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. CAMKIIδ Reinforces Lipid Metabolism and Promotes the Development of B Cell Lymphoma.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 2 countries.

Xiaoqian LiuDepartment of Hematology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, Shandong, China.
Senlin XuMolecular and Cellular Biology of Cancer Program & Department of Diabetes Complications and Metabolism, Beckman Research Institute, City of Hope, Duarte, California, USA.ORCID https://orcid.org/0000-0001-6625-5370
Jiawei ZhangMolecular and Cellular Biology of Cancer Program & Department of Diabetes Complications and Metabolism, Beckman Research Institute, City of Hope, Duarte, California, USA.
Mingjie FanMolecular and Cellular Biology of Cancer Program & Department of Diabetes Complications and Metabolism, Beckman Research Institute, City of Hope, Duarte, California, USA.
Jun XieDepartment of Molecular Medicine, City of Hope National Medical Center, Duarte, California, USA.
Bingfeng ZhangDepartment of Molecular Medicine, City of Hope National Medical Center, Duarte, California, USA.
Hongzhi LiDepartment of Molecular Medicine, City of Hope National Medical Center, Duarte, California, USA.
Guohua YuDepartment of Pathology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, Shandong, China.
Yinghui LiuDepartment of Hematology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, Shandong, China.
Yuanfeng ZhangDepartment of Hematology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, Shandong, China.ORCID https://orcid.org/0000-0001-8405-0053
Joo SongDepartment of Pathology, City of Hope National Medical Center, Duarte, California, USA.
David HorneDepartment of Molecular Medicine, City of Hope National Medical Center, Duarte, California, USA.
Wing C ChanDepartment of Pathology, City of Hope National Medical Center, Duarte, California, USA.
Xiaoxia ChuDepartment of Hematology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, Shandong, China.ORCID https://orcid.org/0000-0002-0963-1576
Wendong HuangMolecular and Cellular Biology of Cancer Program & Department of Diabetes Complications and Metabolism, Beckman Research Institute, City of Hope, Duarte, California, USA.ORCID https://orcid.org/0000-0003-3735-9466
City Of Hope National Medical Center · USQingdao University · CNCity of Hope · US

Funding

Transgenic Mouse FacilityP30CA033572 · NCI · CITY OF HOPE/BECKMAN RESEARCH INSTITUTE · PI XIWEI WU · 1985 to 2026
$86.3M
Transplant for Lymphoma:Therapy-Related LeukemiaP50CA107399 · NCI · CITY OF HOPE/BECKMAN RESEARCH INSTITUTE · PI KWAK, LARRY W · 2004 to 2022
$35.5M
MiRNAs in hepatocellular carcinoma development and treatmentR01CA139158 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI HUANG, WENDONG, YU, HUA E · 2011 to 2021
$3.7M
Bile acids and metabolic surgeryR01DK124627 · NIDDK · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI HUANG, WENDONG · 2020 to 2024
$2.0M
NCI NIH HHS P30 CA033572NCI NIH HHS P30CA033572NCI NIH HHS P50 CA107399NCI NIH HHS R01 CA139158NCI NIH HHS R01CA139158NIDDK NIH HHS R01 DK124627
6 · The paper itself

Abstract

Concurrent translocations of MYC and BCL2 lead to abnormal expression of both oncoproteins, which contribute to the aggressive clinical characteristics of double-hit lymphoma (DHL). An effective therapy for DHL remains an unmet clinical need. In this study, we showed that both Ca

Indexed as

Lymphoma, B-CellLymphoma, Large B-Cell, DiffuseProto-Oncogene Proteins c-bcl-2Proto-Oncogene Proteins c-mycCalcium-Calmodulin-Dependent Protein Kinase Type 2Gene RearrangementHumansBCL2 protein, humanCalcium-Calmodulin-Dependent Protein Kinase Type 2Proto-Oncogene Proteins c-bcl-2Proto-Oncogene Proteins c-mycBcl2berbaminecancer treatmentc-Mycdouble-hit lymphoma

Identifiers

PMID35482553
PMCPMC9378491
OpenAlexW4224991170

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.